Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00906373 · ClinicalTrials.gov registry record · Phase 2
A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00906373: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00906373 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 47 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00906373, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.
Primary Outcome
PFS is defined as the time from date of first dose of study drug until the date of objective PD or death due to any cause, whichever occurs first. PD defined as a ≥20% increase in the sum of the longest diameter (LD) of target lesions using as reference the smallest sum LD since baseline or ≥1 new lesions. Participants who died without PD were considered to have progressed on the date of death. Participants who were alive and without PD were censored at the time of the last objective tumor asses
Interventions
- DRUG Sorafenib
- BIOLOGICAL IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)
- BIOLOGICAL IMC-A12 (cixutumumab) - 20 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-05 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
What the finished NCT00906373 record still lists
NCT00906373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which Sorafenib is the first listed.
NCT00906373 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00906373 about?
NCT00906373 is a clinical study titled "A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver". To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.
What is the current status of trial NCT00906373?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2009-05. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00906373?
The interventions under investigation include: Sorafenib (DRUG), IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg) (BIOLOGICAL), IMC-A12 (cixutumumab) - 20 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00906373?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00906373's enrollment target sits among peer trials
47 1283rd of 2000 higher than 715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia